Skip to main content

Advertisement

SpringerLink
Log in

Rabies virus vaccine as an immune adjuvant against cancers and glioblastoma: new studies may resurrect a neglected potential

  • Review Article
  • Published:
Clinical and Translational Oncology Aims and scope Submit manuscript

Abstract

To review the literature about the use of Rabies Virus-Vaccine (RV-V) as an anticancer immunotherapeutic modality in the light of recent findings. The literature search in relevant databases with the following key words: Rabies virus, cancer, remission. Remissions occured following RV-V injections in patients with cervical cancer and melanoma. Pilot clinical studies showed that RV-V injections enhanced survival in glioblastoma patients, which is supported by findings in GL261 mouse glioma model. If public health studies demonstrate protective role of RV-V against certain types of cancers, it can be benefitted as a novel immune adjuvant in clinic.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69–90.

    Article  PubMed  Google Scholar 

  2. Cabanne MB, Ma QD, Mecum L, Jandial R, Siddiqi J, Chen MY. Prevalence of hepatitis B and C in patients with meningiomas and glioblastoma multiforme. Oncol Lett. 2013;5(3):783–6.

    PubMed  PubMed Central  Google Scholar 

  3. Wick MR. Cutaneous melanoma: A current overview. Semin Diagn Pathol. 2016;33(4):225–41.

    Article  PubMed  Google Scholar 

  4. Wood K, Luke JJ. Optimal Use of BRAF Targeting Therapy in the Immunotherapy Era. Curr Oncol Rep. 2016;18(11):67. doi:10.1007/s11912-016-0554-5.

    Article  PubMed  Google Scholar 

  5. Franklin C, Livingstone E, Roesch A, Schilling B, Schadendorf D. Immunotherapy in melanoma: Recent advances and future directions. Eur J Surg Oncol. 2016;S0748–7983(16):30866–966. doi:10.1016/j.ejso.2016.07.145.

    Google Scholar 

  6. Mahoney DJ, Stojdl DF, Laird G. Virus therapy for cancer. Sci Am. 2014;311(5):54–9.

    Article  PubMed  Google Scholar 

  7. DePace N. Sulla Scomparsa di un enorme cancro begetante del callo dell’utero senza cura chirurgica. Ginecoligia. 1912;9:82.

    Google Scholar 

  8. Pack GT. Note on the experimental use of rabies vaccine for melanomatosis. AMA Arch Derm Syphilol. 1950;62(5):694–5.

    Article  CAS  PubMed  Google Scholar 

  9. Higgins GK, Pack GT. The effects of virus therapy on the microscopic structure of human melanomas. Am J Pathol. 1951;27(4):728–9.

    CAS  PubMed  Google Scholar 

  10. Filipov FV. A trial of rabies vaccine treatment of patients with glioblastoma multiforme. Zh Vopr Neirokhir Im NN Burdenko. 1988;3:38–40.

    Google Scholar 

  11. Philipov PV. Adjuvant treatment of brain glioblastoma multiforme wıth rabies vaccine, deferoxamine and d-penicillamine: a pilot study. J Biomed Clin Res. 2009;2(1):49–53.

    Google Scholar 

  12. Bongiorno E, Morin-Brureau M, Barkhouse D, Faber M, Dietzschold B, Hooper D. A novel rabies virus-based glioma immunotherapeutic strategy targeting survivin (P4440). J Immunol. 2013;190(1 Supplement):126-5.

    Google Scholar 

  13. Desai SM, Sehgal PB, Nanavati AN, Shirodkar MV. A rabies-induced serum factor inhibiting Rous sarcoma virus in chicks. J Gen Virol. 1973;19(3):285–93.

    Article  CAS  PubMed  Google Scholar 

  14. Castel G, Chtéoui M, Caignard G, Préhaud C, Méhouas S, Réal E, et al. Peptides that mimic the amino-terminal end of the rabies virus phosphoprotein have antiviral activity. J Virol. 2009;83(20):10808–20.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Carter J, Saunders VA. Virology: principles and applications. Chichester: Wiley; 2007. p. 175.

    Google Scholar 

  16. Yamaoka S, Ito N, Ohka S, Kaneda S, Nakamura H, Agari T, et al. Involvement of the rabies virus phosphoprotein gene in neuroinvasiveness. J Virol. 2013;87(22):12327–38.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Finke S, Conzelmann KK. Replication strategies of rabies virus. Virus Res. 2005;111(2):120–31.

    Article  CAS  PubMed  Google Scholar 

  18. Tuffereau C, Bénéjean J, Blondel D, Kieffer B, Flamand A. Low-affinity nerve-growth factor receptor (P75NTR) can serve as a receptor for rabies virus. EMBO J. 1998;17(24):7250–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Hashem N, Barr ML. Mitogenic effect of rabies vaccine on cultures of lymphocytes in diseases of the nervous system. Lancet. 1963;2(7316):1029–30.

    Article  CAS  PubMed  Google Scholar 

  20. Langevin C, Jaaro H, Bressanelli S, Fainzilber M, Tuffereau C. Rabies virus glycoprotein (RVG) is a trimeric ligand for the N-terminal cysteine-rich domain of the mammalian p75 neurotrophin receptor. J Biol Chem. 2002;277(40):37655–62.

    Article  CAS  PubMed  Google Scholar 

  21. Gao Y, Wang ZY, Zhang J, Zhang Y, Huo H, Wang T, et al. RVG-peptide-linked trimethylated chitosan for delivery of siRNA to the brain. Biomacromolecules. 2014;15(3):1010–8.

    Article  CAS  PubMed  Google Scholar 

  22. Gooding M, Malhotra M, McCarthy DJ, Godinho BM, Cryan JF, Darcy R, et al. Synthesis and characterization of rabies virus glycoprotein-tagged amphiphilic cyclodextrins for siRNA delivery in human glioblastoma cells: in vitro analysis. Eur J Pharm Sci. 2015;71:80–92.

    Article  CAS  PubMed  Google Scholar 

  23. Lebrun A, Portocarrero C, Kean RB, Barkhouse DA, Faber M, Hooper DC. T-bet Is Required for the Rapid Clearance of Attenuated Rabies Virus from Central Nervous System Tissue. J Immunol. 2015;195(9):4358–68.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Hooper DC, Roy A, Kean RB, Phares TW, Barkhouse DA. Therapeutic immune clearance of rabies virus from the CNS. Future Virol. 2011;6(3):387–97.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Saraya A, Wacharapluesadee S, Khawplod P, Tepsumethanon S, Briggs D, Asawavichienjinda T, et al. A preliminary study of chemo- and cytokine responses in rabies vaccine recipients of intradermal and intramuscular regimens. Vaccine. 2010;28(29):4553–7.

    Article  CAS  PubMed  Google Scholar 

  26. Korver K, Boeschoten EW, Krediet RT, van Steenis G, Schellekens PT. Dose-response effects in immunizations with keyhole limpet haemocyanin and rabies vaccine: shift in some immunodeficiency states. Clin Exp Immunol. 1987;70(2):328–35.

    CAS  PubMed  PubMed Central  Google Scholar 

  27. Kopel E, Oren G, Sidi Y, David D. Inadequate antibody response to rabies vaccine in immunocompromised patient. Emerg Infect Dis. 2012;18(9):1493–5.

    Article  PubMed  PubMed Central  Google Scholar 

  28. Giesen A, Gniel D, Malerczyk C. 30 Years of rabies vaccination with Rabipur: a summary of clinical data and global experience. Expert Rev Vaccines. 2015;14(3):351–67.

    Article  CAS  PubMed  Google Scholar 

  29. Huber BT, Hsu PN, Sutkowski N. Virus-encoded superantigens. Microbiol Rev. 1996;60(3):473–82.

    CAS  PubMed  PubMed Central  Google Scholar 

  30. Johnson N, Cunningham AF, Fooks AR. The immune response to rabies virus infection and vaccination. Vaccine. 2010;28(23):3896–901.

    Article  CAS  PubMed  Google Scholar 

  31. Guichard P, Krell T, Chevalier M, Vaysse C, Adam O, Ronzon F, Marco S. Three dimensional morphology of rabies virus studied by cryo-electron tomography. J Struct Biol. 2011;176(1):32–40.

    Article  CAS  PubMed  Google Scholar 

  32. Faiderbe S, Chagnaud JL, Wafflart J, Geffard M. Autoantibodies directed against membrane phospholipid in serum in patients with malignant tumors. C R Acad Sci III. 1989;310(3):49–52.

    CAS  PubMed  Google Scholar 

  33. Lafon M. Rabies virus receptors. J Neurovirol. 2005;11(1):82–7.

    Article  CAS  PubMed  Google Scholar 

  34. Fuster MM, Esko JD. The sweet and sour of cancer: glycans as novel therapeutic targets. Nat Rev Cancer. 2005;5(7):526–42.

    Article  CAS  PubMed  Google Scholar 

  35. Houimel M, Dellagi K. Peptide mimotopes of rabies virus glycoprotein with immunogenic activity. Vaccine. 2009;27(34):4648–55.

    Article  CAS  PubMed  Google Scholar 

  36. Buthelezi SG, Dirr HW, Chakauya E, Chikwamba R, Martens L, Tsekoa TL, Stoychev SH, Vandermarliere E. The Lyssavirus glycoprotein: A key to cross-immunity. Virology. 2016;498:250–6.

    Article  CAS  PubMed  Google Scholar 

  37. Schwartzbaum J, Seweryn M, Holloman C, Harris R, Handelman SK, Rempala GA, Huang RP, Burkholder B, Brandemihl A, Kallberg H, Johannesen TB, Ahlbom A, Feychting M, Grimsrud TK. Association between Prediagnostic Allergy-Related Serum Cytokines and Glioma. PLoS One. 2015;10(9):e0137503. doi:10.1371/journal.pone.0137503.

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Neuro-Academy Research Group, Sisli, Istanbul, Turkey

    M. A. Altinoz

  2. Department of Psychiatry and Psychology, Maastricht University Medical Centre, Maastricht, The Netherlands

    S. Guloksuz

  3. Department of Psychiatry, Yale University School of Medicine, New Haven, CT, USA

    S. Guloksuz

  4. Department of Neurosurgery, Memorial Hospital, Sisli, Istanbul, Turkey

    İ. Elmaci

Authors
  1. M. A. Altinoz
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. S. Guloksuz
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. İ. Elmaci
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to M. A. Altinoz.

Ethics declarations

Informed consent

Since the submitted article is a review study, no informed consents were required.

Research involving human participants and/or animals

This article does not contain any study with human participants or animals performed by any of the authors.

Conflict of interest

The authors declare no conflict of interest.

Ethical statement

This manuscript complies to the Ethical Rules applicable for Clinical and Translational Oncology.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Altinoz, M.A., Guloksuz, S. & Elmaci, İ. Rabies virus vaccine as an immune adjuvant against cancers and glioblastoma: new studies may resurrect a neglected potential. Clin Transl Oncol 19, 785–792 (2017). https://doi.org/10.1007/s12094-017-1613-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12094-017-1613-6

Keywords

Search

Navigation